Harmony Biosciences Holdings (NASDAQ:HRMY) — Market Cap & Net Worth
Market Cap & Net Worth: Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings (NASDAQ:HRMY) has a market capitalization of $1.86 Billion ($1.86 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6551 globally and #1987 in its home market, demonstrating a -0.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harmony Biosciences Holdings's stock price $33.77 by its total outstanding shares 57892676 (57.89 Million). Review total liabilities of Harmony Biosciences Holdings to assess the company's total debt and financial obligations.
Harmony Biosciences Holdings Market Cap History: 2020 to 2026
Harmony Biosciences Holdings's market capitalization history from 2020 to 2026. Data shows change from $2.09 Billion to $1.96 Billion (-1.56% CAGR).
Index Memberships
Harmony Biosciences Holdings is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.08% | #164 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #708 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.11% | #104 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.64 Trillion | 0.10% | #334 of 602 |
Weight: Harmony Biosciences Holdings's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Harmony Biosciences Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harmony Biosciences Holdings's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.49x
Harmony Biosciences Holdings's market cap is 2.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.65x
Harmony Biosciences Holdings's market cap is 13.65 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.09 Billion | $159.74 Million | -$36.94 Million | 13.10x | N/A |
| 2021 | $2.47 Billion | $305.44 Million | $34.60 Million | 8.08x | 71.35x |
| 2022 | $3.19 Billion | $437.86 Million | $181.47 Million | 7.29x | 17.58x |
| 2023 | $1.87 Billion | $582.02 Million | $128.85 Million | 3.21x | 14.51x |
| 2024 | $1.99 Billion | $714.73 Million | $145.49 Million | 2.79x | 13.69x |
| 2025 | $2.17 Billion | $868.45 Million | $158.69 Million | 2.49x | 13.65x |
Competitor Companies of HRMY by Market Capitalization
Companies near Harmony Biosciences Holdings in the global market cap rankings as of June 18, 2026.
Key companies related to Harmony Biosciences Holdings by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Harmony Biosciences Holdings Historical Marketcap From 2020 to 2026
Between 2020 and today, Harmony Biosciences Holdings's market cap moved from $2.09 Billion to $ 1.96 Billion, with a yearly change of -1.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.96 Billion | -9.75% |
| 2025 | $2.17 Billion | +8.75% |
| 2024 | $1.99 Billion | +6.53% |
| 2023 | $1.87 Billion | -41.38% |
| 2022 | $3.19 Billion | +29.22% |
| 2021 | $2.47 Billion | +17.95% |
| 2020 | $2.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Harmony Biosciences Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.86 Billion USD |
| MoneyControl | $1.86 Billion USD |
| MarketWatch | $1.86 Billion USD |
| marketcap.company | $1.86 Billion USD |
| Reuters | $1.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more